By Anthony O. Goriainoff

Acacia Pharma Group PLC said Monday that it has completed its post-approval requirement clinical trial for its Barhemsys drug--used to treat post-operative vomiting and nausea--in individuals with severe renal impairment, and that it will submit the data to the U.S. Food and Drug Administration.

The biopharmaceutical company said the study, which investigated the effects of Barhemsys in individuals with severe renal impairment, showed no clinically relevant difference in the pharmacokinetics--the study of how a drug affects an organism--electrocardiogram parameters or safety profile of Barhemsys on individuals with or without severe renal impairment.

The company said the trial was required by the FDA as part of the drug's approval for the prevention and treatment of postoperative nausea and vomiting.

Write to Anthony O. Goriainoff at anthony.orunagoriainoff@dowjones.com

(END) Dow Jones Newswires

12-13-21 0131ET